In an open-label, phase 2 study evaluating the efficacy and safety of roxadustat in anemic patients receiving chemotherapy for non-myeloid malignancies, the results showed that roxadustat increased Hb without adverse events of tumor progression in patients with chemotherapy-induced anemia regardless of tumor type and chemotherapy regimen (Glaspy et al., 2023). Here, GSTM1 is linked to neoplasm.